Impact of treatment with a Protein Tyrosine Kinase Inhibitor (Genistein) on acute and chronic experimental Schistosoma mansoni infection

Theodor Bilharz Research Institute

Bibliographic Information

Authors: Sobhy M.M.K.; Mahmoud S.S.; El-Sayed S.H.; Rizk E.M.A.; Raafat A.; Negm M.S.I.

Journal: Experimental Parasitology

Publisher: Academic Press Inc.

Publication Date: February 2018

Volume / Issue: Volume 185

Pages: 115–123

ISSN: 144894

DOI: 10.1016/j.exppara.2018.01.013

Scopus: View on Scopus

PubMed: 29331278

Document Type: Article


Authors and Affiliations

Sobhy M.M.K., Medical Parasitology Department, Kasr Al-Ainy School of Medicine, Cairo University, Egypt; Mahmoud S.S., Theodor Bilharz Research Institute, Imbaba, Giza, Egypt; El-Sayed S.H., Theodor Bilharz Research Institute, Imbaba, Giza, Egypt, Medical Parasitology Department, Faculty of Medicine, Helwan University, Cairo, Egypt; Rizk E.M.A., Medical Parasitology Department, Kasr Al-Ainy School of Medicine, Cairo University, Egypt; Raafat A., Medical Parasitology Department, Kasr Al-Ainy School of Medicine, Cairo University, Egypt; Negm M.S.I., Pathology Department, Kasr Al-Ainy School of Medicine, Cairo University, Egypt


Abstract

Schistosomiasis mansoni is considered one of the most common fibrotic diseases resulting from inflammation and deposition of fibrous tissue around parasitic eggs trapped in the liver, causing morbidity and mortality. Chemotherapy against schistosomiasis is largely dependent on Praziquantel (PZQ). Yet, the huge administration of it in endemic areas and its incompetence towards the immature stages have raised serious alarms against the development of drug resistance. Few drugs are directed to reverse schistosomal liver fibrosis, particularly at the chronic and advanced stages of the disease. Recently, protein tyrosine kinase (PTK) inhibitors have been identified as potent anti-schistosomal and anti-fibrotic drugs against schistosomes, that may suppress and reverse Schistosoma mansoni (S. mansoni) induced liver fibrosis. The present study was designed to assess the anti-schistosomal and antifibrotic activity of Genistein, a PTK inhibitor, in comparison to PZQ, on both acute and chronic S. mansoni-infected mice using different parasitological, histopathological and immunohistochemical studies. Genistein showed a significant reduction (P <.05) in total worm burden, tissue egg load, mean hepatic granulomas diameter and numbers, percentage of collagen and expression of transforming growth factor-beta 1 (TGF-β 1) in the examined hepatocytes with elevation in percentage of degenerated ova, in comparison to the control groups, in both acute and chronic stages of infection. The best results were obtained when Genistein was combined with PZQ. Therefore, it was concluded that Genistein showed a promising anti-schistosomal and anti-fibrotic properties which could make it one of the new potential targets in chemotherapy against schistosomiasis. © 2018 Elsevier Inc.


Keywords

Antifibrotic; Collagen; Genistein; Praziquantel; Schistosoma mansoni; TGF-β 1; Acute Disease; Animals; Anthelmintics; Biomphalaria; Chronic Disease; Female; Granuloma; Image Processing, Computer-Assisted; Immunohistochemistry; Liver; Liver Cirrhosis; Male; Mice; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Schistosomiasis mansoni; transforming growth factor beta1; anthelmintic agent; protein kinase inhibitor; protein tyrosine kinase; animal cell; animal experiment; animal model; animal tissue; Article; controlled study; drug mechanism; experimental bacterial infection; histopathology; liver cell; liver granuloma; mouse; nonhuman; parasitology; priority journal; protein expression; Swiss Webster mouse; tumor number; tumor volume; worm burden; animal; antagonists and inhibitors; chemistry; drug effects; image processing; pathogenicity; pathology; veterinary


Citation Information

Scopus Citations: 31


For comprehensive information about the Theodor Bilharz Research Institute (TBRI), its institutional activities, scientific and research achievements, clinical and hospital services, and the diverse expertise offered through its 22 specialized research and clinical departments, as well as opportunities for professional training, specialized workshops, and scientific conferences, readers are invited to visit the Institute’s official website.

The website provides regularly updated information on the Institute’s latest news, research activities, scientific initiatives, clinical services, institutional programs, and academic and professional opportunities.

English Website: https://www.tbri.sci.eg/en/

Arabic Website: https://www.tbri.sci.eg/ar/

Prepared and Uploaded by:

Abdalla F. Abdalla

Electronic Portal Unit

Electronic Portal Unit

Popular Posts

A cost-performance index for nano-optical biosensor evaluation: Systematic evaluation of europium–salicylate luminescent platforms for GPC3-targeted early HCC diagnosis

Interpretation of liver stiffness measurement in patients with mixed liver disease etiologies

Variable clinical presentations of pulmonary hydatid cysts: a four-case series from a single center in United Arab Emirates, non-endemic region

Holothuria arenicola Extract-Loaded Polycaprolactone Nanocapsules Attenuate Bile Duct Ligation-Induced Acute Liver Injury

Mytilus edulis-mediated green synthesis of selenium nanoparticles with antimicrobial and molluscicidal applications

Corrigendum to ‘Eco-friendly approach for the removal and simultaneous detection of cyanide toxins from drinking and wastewater sources’ [Environ. Pollut. 385 (2025) 127094]

Multifunctional polycaprolactone-based composite fibers with icariin and glutathione for effective repair of critical-sized bone defects